新辅助化疗后保留乳房手术治疗进展期乳腺癌可行性分析

doi:10.11904/j.issn.1002-3070.2016.02.003

实用肿瘤学杂志 ›› 2016, Vol. 30 ›› Issue (2): 109-113.doi: 10.11904/j.issn.1002-3070.2016.02.003

新辅助化疗后保留乳房手术治疗进展期乳腺癌可行性分析

戴猛¹, 李锐¹, 刘贵庭², 梁金龙¹, 冯金发¹, 徐善勇¹

1.黑龙江省医院南岗分院普外科(哈尔滨 150001);
2.牡丹江医学院附属红旗医院胸外科

收稿日期:2015-02-03 出版日期:2016-04-28 发布日期:2016-04-28
通讯作者: 徐善勇,E-mail:diamond561@163.com
作者简介:戴猛,男,(1982-),硕士,主治医师,从事普外科的工作
基金资助:
黑龙江省卫生厅科研课题项目(2012-375);哈尔滨市应用技术与开发项目(2014RFQGJ188)

The feasibility analysis of breast conserving surgery after neoadjuvant chemotherapy in the treatment with advanced breast cancer

DAI Meng¹, LI Rui¹, LIU Guiting², LIANG Jinlong¹, FENG Jinfa¹, XU Shanyong¹

1.Department of General Surgery,Nangang Branch of Heilongjiang Provincial Hospital,Harbin 150001,China;
2.Department of Thoracic Surgery,Hongqi Hospital Affiliated to Mudanjiang Medical College

Received:2015-02-03 Online:2016-04-28 Published:2016-04-28

摘要/Abstract

摘要： 目的对新辅助化疗后保留乳房手术治疗进展期乳腺癌行可行性分析。方法收集2010年6月—2011年6月间进展期乳腺癌患者60例,根据患者意愿分为新辅助化疗后保乳手术组和改良根治术组,每组30例,分别给予新辅助化疗后保乳手术及改良根治手术,随访3年。比较两组的治疗效果,并分析两组乳腺癌循环肿瘤细胞(CTCs)阳性情况,记录两组患者随访后期局部复发率、远处转移率、总生存率和无瘤生存率。结果新辅助化疗后保乳手术组与改良根治术组相比,两组CTCs检出率没有统计学差异(P＞0.05),两组患者在临床完全缓解率、部分缓解率、疾病稳定率以及局部复发率、远处转移率、总生存率和无瘤生存率方面均无统计学差异(P＞0.05)。结论对进展期乳腺癌患者应用新辅助化疗合并保乳手术治疗,能达到与改良根治术类似的治疗效果,可作为治疗进展期乳腺癌的一种选择。

关键词: 保留乳房手术, 新辅助化疗, 进展期乳腺癌, 可行性分析

Abstract: Objective To analyse the breast conserving surgery feasibility in patients with advanced breast cancer after neoadjuvant chemotherapy.Methods Sixty patients with advanced breast cancer were collected from June 2010 to June 2011,and were divided into breast conserving surgery after neoadjuvant chemotherapy group and modified radical mastectomy group according to the intention,30 cases in each group.They were given breast conserving surgery after neoadjuvant chemotherapy and modified radical mastectomy respectively,with following-up for 3 years.The treatment effect and contrast analysis of two groups of breast cancer CTCs positive of the two groups were compared,two groups of late follow-up of patients with local recurrence and distant metastasis rate,overall survival and disease free survival rate were recorded.Results Compared with the modified radical mastectomy group,CTCs detection rate in breast conserving surgery group had no statistical differences(P＞0.05).Two groups of patients in clinical complete remission rate,partial remission rate,disease stability factor and local recurrence and distant metastasis rate,overall survival and disease free survival rate had no statistical significances(P＞0.05).Conclusion The application of breast conserving surgery after neoadjuvant chemotherapy for patients with advanced breast cancer can achieve similar effect as modified radical mastectomy surgery treatment,and can be used as a effective treatment for advanced breast cancer.

Key words: Breast conserving surgery, Neoadjuvant chemotherapy, Advanced breast cancer, Feasibility analysis

中图分类号:

R737.9

戴猛, 李锐, 刘贵庭, 梁金龙, 冯金发, 徐善勇. 新辅助化疗后保留乳房手术治疗进展期乳腺癌可行性分析[J]. 实用肿瘤学杂志, 2016, 30(2): 109-113.

DAI Meng, LI Rui, LIU Guiting, LIANG Jinlong, FENG Jinfa, XU Shanyong. The feasibility analysis of breast conserving surgery after neoadjuvant chemotherapy in the treatment with advanced breast cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 109-113.

参考文献

1 Bonev V,Evangelista M,Chen JH,et al.Long-term follow-up of breast-conserving therapy in patients with inflammatory breast cancer treated with neoadjuvant chemotherapy[J].Am Surg,2014,80(10):940-943.
2 Matsuda N,Hayashi N,Ohde S,et al.A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy[J].J Surg Oncol,2014,109(8):764-769.
3 Vergine M,Scipioni P,Garritano S,et al.Breast-conserving surgery after neoadjuvant chemotherapy in patients with locally advanced cancer.Preliminary results[J].G chir,2013,34(9/10):254-256.
4 Caudle AS,Kuerer HM.Breast conservation therapy after neoadjuvant chemotherapy:optimization of a multimodality approach[J].J Surg Oncol,2014,110(1):32-36.
5 Carpenter R,Doughty JC,Cordiner C.Optimum duration of neoadjuvant letrozole to permit breast conserving surgery[J].Breast Cancer Res Treat,2014,144(3):569-576.
6 Povoski SP,Jimenez RE,Wang WP,et al.Standardized and reproducible methodology for the comprehensive and systematic assessment of surgical resection margins during breast-conserving surgery for invasive breast cancer[J].BMC Cancer,2009,9:254.
7 Najafi YM,Ebrahimi YM,Kaviani YA,et al.Breast conserving surgery versus mastectomy:cancer practice by general surgeons in Iran[J].BMC Cancer,2005,5:35.
8 Madaras L,Kovács KA,Szász AM,et al.Clinicopathological features and prognosis of pregnancy associated breast cancer-a matched case control study[J].Pathol Oncol Res,2014,20(3):581-590.
9 郭贵龙,尤捷,陈学敏.乳腺癌的保乳治疗(附76例报告)[J].实用肿瘤学杂志,2007,21(6):532-535.
10 Nakamura S,Kenjo H,Nishio T,et al.3D-MR mammography-guided breast conserving surgery after neoadjuvant chemotherapy:clinical results and future perspectives with reference to FDG-PET[J].Breast Cancer,2001,8(4):351-354.
11 Inaji H,Komoike Y,Motomura K,et al.Breast-conserving treatment after neoadjuvant chemotherapy in large breast cancer[J].Breast Cancer,2002,9(1):20-25.
12 高影,程流泉,刘梅.MRI对局部进展期乳腺癌新辅助化疗早期疗效评价[J].中国医学影像学杂志,2012,20(5):321-324.
13 Mamounas EP.Impact of neoadjuvant chemotherapy on locoregional surgical treatment of breast cancer[J].Ann Surg Oncol,2015,22(5):1425-1433.
14 陈文有,刘静,毛顺宝.多西他赛+表阿霉素方案在乳腺癌新辅助化疗中的应用[J].山西医药杂志,2013,42(13):745-746.
15 白海亚,龚晓军,刘慧民.CD4+/CD8+在评价局部进展期乳腺癌新辅助化疗疗效中的应用价值[J].中国优生优育,2014,20(3):129-132.
16 Akashi-Tanaka S,Fukutomi T,Sato N,et al.The use of contrast-enhanced computed tomography before neoadjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery[J].Ann Surg,2004,239(2):238-243.
17 张勇,秦贤举,倪旭东.ⅢA期乳癌新辅助化疗后保乳手术的探讨[J].实用肿瘤学杂志,2004,18(2):114-115.
18 Julius T,Kemp SE,Kneeshaw PJ.MRI and conservative treatment of locally advanced breast cancer[J].Eur J Surg Oncol,2005,31(10):1129-1134.
19 Huober J,Krainick-Strobel U,Kurek R.Neoadjuvant endocrine therapy in primary breast cancer[J].Clin Breast Cancer,2004,5(5):341-347.

[1]	黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.
[2]	陈力, 张玉新, 左艳娇, 马菲, 宋洪江, 薛英威. SOX和XELOX在进展期胃癌新辅助化疗中的临床疗效比较[J]. 实用肿瘤学杂志, 2017, 31(1): 23-30.
[3]	巴志昌, 王欣欣, 崔万辉, 国飞, 张修石. MRI弥散加权成像对宫颈癌新辅助化疗评估的应用价值[J]. 实用肿瘤学杂志, 2015, 29(6): 518-522.
[4]	朱宏, 朱莉, 韩世愈, 方芳, 于洋. 磁共振弥散加权成像对宫颈癌新辅助化疗后无进展生存期的预测价值[J]. 实用肿瘤学杂志, 2014, 28(6): 519-523.
[5]	宁四清, 詹波涛, 徐海声. TNP方案在头颈部鳞状细胞癌中的疗效探讨[J]. 实用肿瘤学杂志, 2014, 28(6): 540-544.
[6]	宋雨霖综述, 王晶审校. 卵巢癌术前新辅助化疗筛选与评估的展望[J]. 实用肿瘤学杂志, 2014, 28(6): 553-556.
[7]	马荣, 陈曦海, 耿晓星, 刘爽, 张恒. 术前同期放化疗对局部晚期宫颈癌近期疗效的综合评价[J]. 实用肿瘤学杂志, 2012, 26(4): 314-318.
[8]	滕冲, 宋晓薇, 蔡莉. Ki-67在乳腺癌新辅助化疗中的作用及临床意义[J]. 实用肿瘤学杂志, 2012, 26(2): 188-192.
[9]	刘扬, 庞达. 乳腺癌新辅助化疗前后Ki-67、HER-2、ER和PR的变化与临床缓解率的关系[J]. 实用肿瘤学杂志, 2011, 25(5): 442-445.
[10]	张一君, 邹天宁, 陈杨萍, 陈艳. 乳腺癌新辅助化疗疗效评价及预测的研究进展[J]. 实用肿瘤学杂志, 2011, 25(5): 477-481.
[11]	印明柱, 娄阁, 陈秀玮, 顾泰华. 新辅助化疗后根治性手术与同步放化疗在局部晚期宫颈癌的远期疗效评价^△[J]. 实用肿瘤学杂志, 2011, 25(1): 40-45.
[12]	张斌. 乳腺癌新辅助化疗应该注意的几个问题[J]. 实用肿瘤学杂志, 2010, 24(6): 502-505.
[13]	单明, 张显玉, 贺晓光, 张国强. 早期乳腺癌规范化保乳治疗的回顾性分析[J]. 实用肿瘤学杂志, 2010, 24(4): 348-351.
[14]	吴良芝, 江南, 张艺. 两种新辅助化疗对局部晚期宫颈癌分子疗效的研究[J]. 实用肿瘤学杂志, 2009, 23(5): 427-429.
[15]	顾太华, 娄阁. 局部晚期宫颈癌新辅助化疗近期疗效及生存研究^△[J]. 实用肿瘤学杂志, 2009, 23(3): 238-241.

新辅助化疗后保留乳房手术治疗进展期乳腺癌可行性分析

The feasibility analysis of breast conserving surgery after neoadjuvant chemotherapy in the treatment with advanced breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价